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Clinics and pathology 
Disease 
Chronic lymphoproliferation 
Phenotype/cell stem origin 
B-cell disease; the existence of rare cases of T-CLL has 
been debated. 
Epidemiology 
Annual incidence 30/106; represents 70% of lymphoid 
leukaemias, 1/4 of all leukaemias; median age: 60-80 
yrs, 2M/1F. 
Clinics 
Diagnosis is often delayed, due to the lack of sympto s 
(therefore, median survival from the begining of the 
disease may be much more than median survival from 
diagnosis).  
The patient may present with enlarged lymph nodes, 
splenomegaly, lymphocytosis > 45X109/l; 
hypogammaglobulinemia in 60%. 
Cytology 
Typically, proliferation of mature small lymphocytes of 
normal morphology; lymphocytes with more abundant 
cytoplasm may be present. When prolymphocytes are 
10% or greater they are classified as 'chronic 
lymphocytic leukaemia-prolymphocytic leukaemia'. 
The main immunophenotypic features that define B-
CLL are: the predominant population shares B-cell 
markers CD19, CD20, and CD23 with the CD5 
antigen, in the absence of other pan-T-cell markers; the 
B-cell is monoclonal with regard to expression of eith r 
kappa or lambda; and surface  
immunoglobulin (slg) is of low density. Not only are 
these characteristics generally adequate for a precise 
diagnosis, but, importantly, they distinguish CLL from 
uncommon disorders such as PLL, hairy-cell leukemia, 
mantle-cell lymphoma, and other lymphomas. Further, 
the Matutes score based on the most common marker 
profile in CLL, CD5+, CD23+, FMC7- and weak 
expression (+/-) of surface immunoglobulin (SIg) and 
CD22, can distinguish between typical and atypical 
CLL by assigning scores that range from 5 (typical of 
CLL) to 0 (atypical for CLL). 
Treatment 
Binet staging is used for therapeutic intervention. The 
treatments options are: watchful waiting for symptoms, 
radiation therapy, chemotherapy, surgery such as 
splenectomy. Those being tested in clinical trails re
monoclonal antibodies, chemotherapy with stem cell 
transplant. 
Prognosis 
Evolution: unrelated causes and disease-related 
infections are the 2 major causes of death; others: 
autoimmune hemolytic anaemia and thrombocytopenia; 
transformation into Richter's disease or into 
prolymphocytic leukaemia (in 10%). Some patients 
with CLL survive for many years without therapy with 
minimal signs and symptoms, during the entire disease 
course and have a survival time similar to age-matched 
controls, whereas others have a rapidly deteriorating 
blood counts and organomegaly. Rai et al and Binet et 
al devised staging: less than 3 lymph nodes, HGB. 
Since more than 80% CLL are diagnosed at early 
disease stages, many prognostic markers have been 
identified. One of the most important molecular genetic 
markers defining pathogenic and prognostic subgroups 
of CLL is the mutation status of VH gene. Surrogate 
markers for VH status are CD38 and ZAP-70 and their 
validity has yielded controversial results. Patients with 
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few or no VH mutations or many CD38+ or ZAP-70+ 
B cells have an aggressive usually fatal course, whreas 
patients with mutated clones or few CD38+ or ZAP-
70+ B cells have an indolent course. 
Genomic aberrations are the other genetic parameter 
shown to be of prognostic relevance in CLL. 
Cytogenetics 
Cytogenetics morphological 
Clonal anomaly is found in about 50% of cases by 
chromosome analysis and in about 80% of CLL cases 
by fluorescence in situ hybridization (FISH) of 
interphase cell nuclei with a disease-specific 
comprehensive probe set. The disease progression as 
assessed by the treatment-free interval for 17p deletion 
(n=23), 11q deletion (n=56), 12q trisomy (n=47), 
normal (n=57) and 13q deletion (single abnormality: 
n=117) were 9, 13, 33, 49, and 92 months respectively; 
and the survival probabilities were 32, 79, 114, 111 and 
133 months respectively. 
Complex karyotypes are found in 10%; unrelated 
clones demonstrating the existence of cells 
subpopulations are frequent findings in this disease. 
Trisomy12, found in 15-20% [cytogenetics] or 16-25 % 
[FISH] of CLL cases has an unresolved pathogenic 
impact, and intermediate outcome. In other studies, 
trisomy 12 is an adverse prognostic factor (median 
survival: 5 yrs); found either as the sole anomaly, s an 
anomaly accompanied by others, or even as an 
accompanying (secondary) anomaly; present only in a 
subset of the malignant cell population; Trisomy 12 is 
found frequently in atypical lymphocyte morphology 
and CD5- cases, often with an increased number of 
prolymphocytes. 
The most common deletion, del(13)(q14.3) found in 
10-20% [cytogenetics] or 36-64% [FISH] CLL cases 
includes a nontranscribed gene and two micro-RNA 
genes. As the sole abnormality, has good prognosis. 
The disease free interval and overall survival is better 
than cases with normal karyotype because of slow 
disease progression. 
Deletion 11q22-q23, involving ATM gene, is marked 
by lymphadenopathy and poor survival and is detected 
in 11-18% [FISH] of CLL cases. 
Deletion 17p13 (p53) occurs in 7-8% [FISH] of CLL 
cases that are resistant to chemotherapy and have a 
short survival. 
Although, 14q32 involvement was frequent in early 
CLL studies, currently, t(11;14)(q13;q32) with BCL1 / 
IgH rearrangement, is considered to be a hallmark of 
mantle cell lymphoma, similarly other rare 14q32 
rearrangements such as CLL; t(14;19)(q32;q13), are 
associated with leukemic lymphoma. Therefore, 
translocations involving 14q32 IgH locus are probably 
diseases other than CLL. Eliminating t(11;14) and 
t(14;18), 14q32 rearrangements are found in about 4% 
of cases studied by FISH. 
IgH deletion may be hetero- or homozygous. A 14q32 
involvement is considered a good prognostic feature 
(median survival > 15 yrs) in CLL. As in other B-cell 
chronic leukaemias or lymphomas; t(11;14)(q13;q32), 
typical of mantle cell lymphoma with BCL1/IgH 
rearrangement, t(14;19)(q32;q13) with BCL3/IgH 
rearrangement, may be associated with short survival, 
t(2;14)(p13;q32), exceptional; and other t(14;var) may 
occasionally be found in CLL. 
Other recurring anomalies are del(6q) [0-6% by FISH], 
+8q24 [5% by FISH], +3, and +18. Deletion 6q21 has a 
poor prognosis. 
Genes involved and proteins 
Note 
Genes involved as a primary event are still unknown. 
ATM and P53 are deleted in 11q and 17p deletions, 
respectively. 
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